A new risk stratification model for idiopathic pulmonary fibrosis could shift treatment from passive monitoring to active, goal-oriented care.

Regulatory officials have granted Molbreevi priority review and assigned a goal date of Aug. 22, 2026. If approved, Molbreevi will be priced between $400,000 and $500,000 per year.

Insufficient evidence exists to show efficacy of novel hypersensitivity pneumonitis therapies, indicating the need for clinical protocols.

Relapse rates over 3 years did not differ with glucocorticoid withdrawal vs maintenance among patients with stable SjD-ILD.

Cough sounds carry disease-specific acoustic signatures. By analysing these signatures using an AI-based algorithm, the ...